Myelofibrosis successfully treated with prednisolone in a patient with pachydermoperiostosis

Intern Med. 2011;50(19):2207-11. doi: 10.2169/internalmedicine.50.5717. Epub 2011 Oct 1.

Abstract

Pachydermoperiostosis (PDP) is a rare disorder of bone and connective tissue growth. A 21-year-old man was referred to our hospital with anemia. He showed characteristics of PDP. Bone marrow biopsy showed myelofibrosis. Chromosomal abnormalities or JAK2 mutation were not found. Anemia gradually progressed, and he became transfusion-dependent. Oral prednisolone was initiated; it gradually improved his anemia and rendered the patient free of transfusion. However, other clinical symptoms such as clubbed fingers and skin hypertrophy remained unimproved. In this case, the serum concentration of vascular endothelial growth factor and transforming growth factor-β levels were increased. Further investigation will be necessary to establish appropriate treatment strategies for this disease.

Publication types

  • Case Reports

MeSH terms

  • Anemia / complications
  • Anemia / drug therapy
  • Bone Marrow / pathology
  • DNA Mutational Analysis
  • Humans
  • Janus Kinase 2 / genetics
  • Male
  • Osteoarthropathy, Primary Hypertrophic / complications*
  • Osteoarthropathy, Primary Hypertrophic / diagnosis
  • Osteoarthropathy, Primary Hypertrophic / drug therapy*
  • Osteoarthropathy, Secondary Hypertrophic / complications
  • Prednisolone / therapeutic use*
  • Primary Myelofibrosis / complications*
  • Primary Myelofibrosis / diagnosis
  • Primary Myelofibrosis / drug therapy*
  • Transforming Growth Factor beta / blood
  • Vascular Endothelial Growth Factor A / blood
  • Young Adult

Substances

  • Transforming Growth Factor beta
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Prednisolone
  • JAK2 protein, human
  • Janus Kinase 2